2012年-CEPS欧洲政策研究中心_Innovation_in_the_Health_Sector_in_Turkey_on_Its_Way_to_EU_Membership_15页_127kb

Summary of "Innovation in the Health Sector in Turkey on Its Way to European Union Membership"

Core Content

This report examines the current state of innovation in Turkey's health sector, focusing on pharmaceuticals, medical devices, and eHealth services. It outlines the challenges and opportunities Turkey faces in developing a sustainable and efficient innovation environment, particularly in the context of its accession to the European Union (EU).

Main Viewpoints

• Health Sector as a Key Economic Sector: The health sector is a major contributor to GDP and employment in advanced economies. In Turkey, it is expected to grow rapidly, driven by population size, expanding insurance coverage, and technological development.
• Innovation and Efficiency: Innovation in the health sector improves early diagnosis and treatment, which can reduce long-term costs. It also enhances the competitiveness of companies and the nation as a whole.
• Government Role in Innovation: Government policies and regulations play a crucial role in stimulating innovation. They influence R&D investment, pricing, and reimbursement decisions, which are essential for the development and accessibility of new health products and services.
• Need for Public-Private Partnerships: The health sector requires collaboration between public institutions, private companies, and universities to foster innovation. This partnership is especially important in R&D and the development of new technologies.
• EU Harmonization as a Catalyst: Aligning with EU standards and practices is vital for Turkey to integrate into the global health innovation system. This includes intellectual property protection, data sharing, and market transparency.

Key Information

Pharmaceutical Industry

• Market Potential: Turkey's pharmaceutical market reached $10.4 billion in 2009 and is expected to grow rapidly.
• R&D Challenges: R&D investment remains low compared to the EU. In 2009, Turkey's R&D expenditure as a share of GDP was 0.85%, still below the EU average.
• Incentives for Innovation: The report recommends revising R&D legislation to support industrial priorities, including the establishment of a 'Turkish Drug and Medical Devices Institution'.
• Licensing and Pricing: The licensing process should be expedited to 210 days and aligned with EU and US standards. Reimbursement decisions for new medicines should be transparent and predictable.
• Public-Private Collaboration: Universities and research institutions should act as facilitators for public-private partnerships. They need to be supported in R&D and commercialization efforts.

Medical Devices

• Market Growth: Turkey is a significant market for medical devices, with a volume of $2 billion in 2009. It ranks 13th in terms of value added.
• Import Dependency: Imports currently dominate the market, making domestic production less competitive. Tax incentives for local innovation are needed.
• Institutional Support: The establishment of a national medical devices authority and improving interoperability between health institutions are critical.
• Human Capital: There is a need for experienced professionals in various fields (medicine, biotechnology, electronics, etc.) to support innovation. A reversal of brain drain is recommended.
• Regulatory and Legal Framework: The current legal framework lacks sufficient support for innovation. Reforms in data protection, interoperability, and procurement are necessary.

eHealth

• Benefits of eHealth: eHealth improves the accessibility, quality, and efficiency of health services through the use of information and communication technologies.
• Fragmented Development: eHealth applications in Turkey are fragmented and require stronger public regulation and coordination.
• Interoperability Challenges: Lack of interoperability between health data systems and unclear data protection rules hinder the development of eHealth services.
• Stakeholder Involvement: A collaborative approach involving public, private, and academic sectors is essential for the planning and implementation of eHealth systems.
• EU Integration: Aligning with EU eHealth standards, such as the Smart Open Services for European Patients (epSOS), will help Turkey benefit from cross-border patient mobility and expand its market opportunities.

Conclusion

Turkey has significant potential for innovation in the health sector but requires substantial institutional, legal, and financial reforms to realize this potential. Strategic prioritization, public-private partnerships, and alignment with EU standards are essential for fostering sustainable growth and improving the overall health status of the population.